Clinical Trials
8 trialsNCT05803941 2026-06-04
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Novartis
Phase 4 Recruiting
NCT06379217 2026-06-03
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
NCT07145177 2026-06-01
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT05849298 2026-05-27
PSMACare
Novartis
Phase 2 Active not recruiting
NCT05939414 2026-05-27
PSMA-DC
Novartis
Phase 3 Recruiting
NCT06520345 2026-05-27
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT05884255 2026-05-19
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT05413850 2026-05-14
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting